For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
The IL-12 p70 Elispot assay is designed to enumerate cytokine producing cells in a single cell suspension. This method has the advantage of requiring a minimum of in-vitro manipulations allowing cytokine production analysis as close as possible to in-vivo conditions in a highly specific way. This technique is designed to determine the frequency of cytokine producing cells under a given stimulation, and the follow-up of such frequency during a treatment and/or a pathological state. Elispot assay constitutes an ideal tool in the TH1 / TH2 response, vaccine development, viral infection monitoring and treatment, oncology, infectious diseases, autoimmune diseases and transplantation
Principle of Method
The IL-12 p70 Elispot assay is based on sandwich immuno-enzyme technology. Cell secreted cytokines or soluble molecules are captured by coated antibodies avoiding diffusion in supernatant, protease degradation or binding on soluble membrane receptors. After cell removal, the captured cytokines are revealed by a secondary biotinylated detection antibody, which is in turn recognised by streptavidin conjugated to alkaline phosphatase. PVDF-coated-well plates are then incubated with BCIP/NBT substrate. Coloured "purple" spots indicate cytokine production by individual cells.
Recognizes natural human IL12
|Components||10 x 96 tests|
|IL12 p70 Capture antibody (clone B-T21)||2 x 0.5ml|
|IL12 p79 Biotinylated detection antibody (clone B-P24)||2 vials|
|Ready to use substrate buffer||2 x 50ml|
Our Abpromise guarantee covers the use of ab46602 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISpot||Use at an assay dependent dilution.|
ab46602 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"